$XBI $143.32 (+2.04%) 📈
PIPELINE:
$IMRA (-37.97%) - Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
$RDHL (-3.76%) - RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
$RDUS (+15.76%) - Radius Health, Inc. Announces Acquisition of Orphan Disease Program
$SELB (+8.22%) - Selecta Biosciences Announces Data in Non-Human Primates, FurtherValidating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
$ZNTL (-6.54%) - Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
FINANCE:
$RGNX (+8.39%) - Offering